Marc D Cohen

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. ncbi Raising expectations for arthritis treatment. Biologic response modifiers are making remission possible
    Marc D Cohen
    Division of Rheumatology, Mayo Clinic, Jacksonville, FL 32224, USA
    Postgrad Med 116:41-2, 48-50. 2004
  2. ncbi Rheumatologic manifestations of sarcoidosis
    Andy Abril
    Division of Rheumatology, Mayo Clinic, Jacksonville, Florida 32224, USA
    Curr Opin Rheumatol 16:51-5. 2004
  3. ncbi Longitudinal analysis of the use of etanercept versus infliximab determined from medical chart audit
    Jacob Abarca
    University of Arizona College of Pharmacy, Center for Health Outcomes and PharmacoEconomic Research, 1703 E Mabel, P O Box 210207, Tucson, AZ 85721 0207, USA
    J Manag Care Pharm 10:538-42. 2004
  4. ncbi Improving the treatment of rheumatoid arthritis
    Marc D Cohen
    Division of Rheumatology, Mayo Clinic College of Medicine, Jacksonville, Fla, USA
    Manag Care 15:4-14; discussion 15-8. 2006

Collaborators

  • Andy Abril
  • Jacob Abarca
  • Amy J Grizzle
  • Edward P Armstrong
  • Daniel C Malone

Detail Information

Publications4

  1. ncbi Raising expectations for arthritis treatment. Biologic response modifiers are making remission possible
    Marc D Cohen
    Division of Rheumatology, Mayo Clinic, Jacksonville, FL 32224, USA
    Postgrad Med 116:41-2, 48-50. 2004
  2. ncbi Rheumatologic manifestations of sarcoidosis
    Andy Abril
    Division of Rheumatology, Mayo Clinic, Jacksonville, Florida 32224, USA
    Curr Opin Rheumatol 16:51-5. 2004
    ..Often the presence of musculoskeletal findings may lead to the diagnosis of the disease and the institution of the appropriate treatment...
  3. ncbi Longitudinal analysis of the use of etanercept versus infliximab determined from medical chart audit
    Jacob Abarca
    University of Arizona College of Pharmacy, Center for Health Outcomes and PharmacoEconomic Research, 1703 E Mabel, P O Box 210207, Tucson, AZ 85721 0207, USA
    J Manag Care Pharm 10:538-42. 2004
    ..To describe the dosing of etanercept and infliximab for the treatment of rheumatoid arthritis (RA)...
  4. ncbi Improving the treatment of rheumatoid arthritis
    Marc D Cohen
    Division of Rheumatology, Mayo Clinic College of Medicine, Jacksonville, Fla, USA
    Manag Care 15:4-14; discussion 15-8. 2006